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Summary It has been recognized that the tumour markers alpha-fetoprotein (AFP) and human chononic gonadotrophin (HCG) may show a
transient elevation after the initiation of chemotherapy in non-seminomatous testicular cancer. We investigated the prognostic importance of
these so-called marker surges in a cohort of patients treated with cisplatin combination chemotherapy between 1983 and 1991. A total of 669
patients were studied. Of 352 patients who had an elevated AFP at the start of treatment and for whom we had data at both day 1 and day 8.
101 (29%) had a surge. Of 317 patients for whom we had data for HCG. 80 patients (25%) had a surge. It was found that an AFP surge was
a strong adverse prognostic factor for progression [hazard ratio (HR) 2.28. P = 0.005]. There was no statistically significant difference in
survival (HR 1.65. P = 0.13). There was no prognostic significance of a HCG surge, either for progression or for survival. To investigate
whether a surge was an independent prognostic factor for progression and survival, multivariate Cox regression models were fitted using the
independent prognostic factors for progression and survival and the surge/decline variable. An AFP surge was retained in the final model for
progression. A HCG surge was of no prognostic importance for progression or survival. We conclude that an AFP surge has an adverse
prognostic significance. independent of pretreatment characteristics.
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Cisplatin combination chemotherapy yields 70-80%7 long-term
disease-free survival in patients with disseminated testicular non-
seminoma (Levi et al. 1988: Peckham et al. 1988: Roth et al. 1988:
Stoter et al. 1989). Patients w-ho fail treatment are usually charac-
terized bv a hiah tumour load and/or high serum concentrations of
the tumour markers alpha-fetoprotein (AFP) and human chorionic
5onadotrophin (HCG). Multixaniate prognostic factor anal-ses
have led to the dex-elopment of models which can be used to clas-
sify patients as haxing a good. intermediate or poor prognosis on
the basis of criteria at the start of treatment (Bosl et al. 1983:
Medical Research Council Workinc Partx on Testicular Tumours.
1985: Birch et al. 1986: Stoter et al. 1987: Droz et al. 1988:
Hitchins et al. 1989: Stoter and S-lxester. 1990: Aass et al. 1991:
Mead et al. 1992: International Germ Cell Cancer CollaboratiVe
Group. 1997). In addition. it wxould be useful to have a method for
early prediction of an adxerse treatment outcome after the start of
chemotherapy.
The most common pattern of marker response after the initia-
tion of chemotherapy is an exponential regression to normal
levels. However. it has been recognized for many y-ears that
tumour markers mav showx a transient elevation durinn the first
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w-eeks (Vogelzang et al. 1982: Horx-ich and Peckham. 19861.
These so-called marker surges are beliexed to result from the
release of HCG and/or AFP from l-tic tumour cells and miaht
reflect a hiah sensitivitv of the tumour cells to the chemotherapy.
In the initial reports in small series of patients. no prognostic
significance ofa surge was established. To date. neither the precise
incidence of marker surges nor its possible implications have been
reported. In the current study. w-e inxestigated the prognostic
importance of marker surges in a total of 669 patients treated w-ith
cisplatin combination chemotherapy for metastatic non-semino-
matous testicular cancer between 1983 and 1991.
PATIENTS AND METHODS
Patients
The 669 patients in this study were treated in the framework oftw-o
simultaneous randomized trials of the European Organization for
Research and Treatment of Cancer (EORTC) (Wit de et al. 1995.
1997). In the first study. 250 patients with lmph node metastases
> 5 cm and/or lung metastases >2 cm and/or HCG > 10 000 IU F'
and/or AFP > 1000 /IL-1 xwere treated with cisplatin. etoposide
and bleom-cin (BEP) or an alternating regimen of BEP and
cisplatin. vinblastine. and bleomycin (PVB). In the other study.
419 patients wxho had smaller metastases and low-er marker lexels
than specified aboxve were treated with BEP or EP In both proto-
cols. induction chemotherapy consisted of four treatment cycles
for a total duration of 12 weeks. After four c%-cles of
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Table 1 Numbers of patients for whom there was an elevated marker value at day 1 and a known value around day 8
Patients Equal value Decline (%) Surge (%) Included
with data or < 10% in the
at days 1 and 8 decrease (%) analysis
AFP 352 58 (16) 193 (55) 101 (29) 294
HCG 317 48 (15) 189 (60) 80 (25) 269
chemotherapy, patients with normal markers and no residual
tumour mass did not receive further therapy. Patients with normal
markers but residual tumour mass were subjected to debulking
surgery. In case of viable cancer in the surgical specimens, two
additional cycles ofchemotherapy were given.
At the time of this analysis, the median follow-up was 9.3 years
and the maximum was 12.7 years. Treatment failure was defined
as elevated tumour markers after four induction chemotherapy
cycles, viable cancer in the resected specimens, relapse from















Serum marker values and definitions
In determining whether a surge occurred, the first value that was
used was the value on the day at the start ofchemotherapy, day 1.
The second sample was the first value obtained during the admin-
istration of the first cycle of chemotherapy, which was usually
around day 8 at the time of the second administration of
bleomycin. A surge was defined as any increase in marker levels
(value day 8 > day 1). A decline was defined as a greater than 10%
decrease. Patients with less than or equal to 10% decreases were
excluded from the analysis because it is unclear whether such
values truly represent a decline, or whether a surge may have
occurred one or several days before this second measurement
point.
Statistical methods
Progression-free rates and survival rates were estimated using the
Kaplan-Meier technique (Kaplan and Meier, 1958). Univariate
and multivariate analyses of the time to progression and of the
duration of survival were performed using Cox proportional
hazards regression models (Cox, 1972). A 0.05 significance level
was used in all analyses. All variables which were significant in
the univariate analysis were entered in the first step of the multi-
variate model. A step-down procedure was then applied to deter-
mine those factors of most prognostic importance. The effect of a
variable is described using the hazard ratio (HR) together with its
95% confidence interval (CI). The logistic regression model (Cox
and Snell, 1989) was used to determine whether there was an
association between the patients' initial characteristics and the
occurrence of a surge.
RESULTS
Number of patients
HCG and AFP values at the start of chemotherapy were available
in 656 and 655 patients respectively. Of these patients, 383 (58%)
had an elevated HCG at the start of treatment, and 413 (63%) had
an elevated AFP. The actual numbers of patients for whom there
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Number of patients at risk
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Figure 2 Duration of survival - AFP surge/decline
was an elevated value at day 1 and a known value around day 8,
and the numbers of patients entered in the analysis, are shown in
Table 1. Of 352 patients with an elevated AFP, 101 (29%) had a
surge with a median increase of 32% (range 1-300%). Of 317
patients with an elevated HCG, 80 (25%) had a surge with a
median increase of49% (range 1-300%).
Analysis plan
The analysis of a surge as a univariate prognostic factor for
progression and survival is shown in Figures 1 and 2. It was found
that an AFP surge was a strong adverse prognostic factor for
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Table 2 Pretreatment characteristics as prognostic factors
Variable P-value HR 95% Cl
Time to progression
Presence and size of retroperrtoneal metastases 0.0001 (2 df)
Presence 0.27 0.12-0.62
Size 2.36 1.71-3.27
Presence of mediastinal metastases 0.001 2.47 1.44-.22
Size of pulmonary metastases 0.01 1.49 1.10-2.04
Overall survival
AFP at the start of treatment 0.016 1.98 1.13-3.44
Presence and size of retroperitoneal metastases 0.0001 (2df)
Presence 0.27 0.10-0.71
Size 2.83 2.02-3.96
Number of pulmonary metastases 0.0001 1.98 1.45-2.72
*Denotes degree of freedom.
Table 3 AFP surge as a prognostic factor in the mulftivariate analysis
Variable P-value HR 95%CI
AFP surge and progression
AFP surge (surge/decline) 0.007 1.46 1.11-1.92
Presence and size of retroperitoneal metastases 0.0007 (2 df)
Presence 0.37 0.13-1.06
Size 2.02 1.39-2.92
Size of pulmonary metastases 0.0007 1.94 1.32-2.85
AFP surge and survival
AFP at the start of treatment 0.004 2.72 1.38-5.40
Presence and size of retroperitoneal metastases 0.002 (2 df)
Presence 0.24 0.07-0.84
Size 2.18 1.41-3.37
Number of pulmonary metastases 0.03 2.32 1.07-5.01
*Denotes degree of freedom.
Table 4 Mulftivariate models using AFP surge and the IGCCCG classification
Variable P-value HR 95% Cl
AFP surge and progression
IGCCCG risk group (goodVintermediate vs poor) 0.0001 4.07 2.34-7.09
AFP surge (surge vs decline) 0.01 1.41 1.08-1.85
AFP surge and survival
IGCCCG risk group (good/intermediate vs poor) 0.0001 4.52 2.41-8.49
AFP surge (surge vs decline) 0.22 1.21 0.89-1.66
progression (HR 2.28: Cl 1.28-4.04: P = 0.005: Figure 1). There
was no statisticallv significant difference in survival (HR 1.65: CI
0.86-3.18: P = 0.13: Figure 2). As can be seen in Figure 2. the
curves suggest a possible effect. but the number of deaths is low.
thus. the power for detecting an effect is also low. There was no
prognostic significance of an HCG surge. neither for progression
(HR 1.07: CI 0.59-1.95: P = 0.82) nor for survival (HR 1.23: CI
0.61-2.47: P = 0.56).
Because it was considered that a surge was possibly related to a
high initial value. which is an adverse prognostic factor in itself.
we separated initial values ofless than or equal to 1000 IU 1-' from
values above 1000 IU 1-1. We found that the progression hazard
ratios of an AFP surge were almost identical in both groups (HR
2.33: CI 1.17-4.62) for initial AFP < 1000WIU 1-1. and for initial
AFP> 1000 R 1-' (HR 2.16: CI 0.76-6.15).
To investigate whether a marker surge adds to the prognostic
ability of other baseline characteristics. further univariate and
multivariate analyses were performed. including an analysis ofthe
association between the pretreatment characteristics ofthe patients
and the probability of having a surge in AFP or HCG. univanrate
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20 20 Overall logrank test: P=0.0714
10
0 2 4 6 8 10 12 14
Years
0 N Number of patients at risk AFP change
17 165 148 142 108 81 43 1 Decline
15 82 66 64 54 36 16 1 ---Surge
Figure 3 Progression according to AFP surge/decline in good/intermediate
prognosis for disease according to the IGCCCG
and multivariate analyses of the pretreatment characteristics as
prognostic factors for the end points progression and survival, and
a Cox regression model in which we analysed surge/decline as a
covariate for progression and survival along with the pretreatment
prognostic factors.
Univariate analysis of the relationship of the
pretreatment characteristics with a surge
To detect any pretreatment characteristics which could potentially
explain the prognostic impact of a surge in AFP or HCG on the
patient's outcome, analyses of the relationship between the
pretreatment characteristics [including histology, initial marker
values, size and extent of metastases, the overall risk group
according to the International Germ Cell Cancer Collaborative
Group (IGCCCG) classification (International Germ Cell Cancer
Collaborative Group, 1997)] and the probability ofhaving a surge
in AFP or HCG values were performed. None of the variables
were significantly related to either a surge in AFP or a surge in
HCG in the univariate logistic regression models (data not shown).
Univariate and multivariate analysis of the pretreatment
characteristics as prognostic factors for progression
and survival
Both univariate and multivariate evaluations of the pretreatment
characteristics as possible prognostic factors for progression and
survival were carried out. Univariately, both for progression and
for survival, the initial marker values, the presence and size of
nodal disease, the presence and size of pulmonary metastases,
and the presence of non-pulmonary visceral metastases were
confirmed to be significant parameters (data not shown). The
prognostic factors that were retained in the final multivariate
models for progression and survival are shown in Table 2.
Marker surge as prognostic factor for progression and
survival in the multivariate analysis
Subsequently, the surge/decline variable was entered in the multi-
variate analysis by fitting multivariate Cox regression models for










20 Test for linear trend P=0.0007
10
0 2 4 6 8 10 12 14
Years
0 N Number of patients at risk AFP change
26 193 167 161 123 91 45 1 Decline
10 50 41 38 33 23 10 0----Surge 30%
17 51 33 32 27 17 8 2- Surge>30%
Figure 4 Progression according to the percentage change in AFP
pretreatment factors as variables. In the analysis oftime to progres-
sion, AFP surge was retained in the final model (Table 3), indicating
that AFP surge adds prognostic information to that contained in the
pretreatment prognostic factors. In the analysis using survival as the
end point, AFP surge was not retained in the final model (Table 3).
As expected from the univariate analysis, HCG surge did not appear
to be a prognostic factor for either progression or survival (data not
shown).
In addition, multivariate models were fitted using only the
surge/decline variable and the risk group according to the
IGCCCG classification. For this purpose, the classification
good/intermediate versus poor prognosis was used because in our
data set the difference in time to progression and survival between
the poor prognosis group and the good/intermediate prognosis
group was much larger than the difference between the good prog-
nosis and the intermediate prognosis group (30% vs 10%).
In the analysis for progression, it was again found that AFP
surge is a significant predictor for progression, independent ofthe
IGCCCG classification (HR 1.41; CI 1.08-1.85; P = 0.013), thus,
adding to the strong predictive power of the IGCCCG classifica-
tion (Table 4). An AFP surge did not add to the prediction of
survival, once the risk group was known.
Figure 3 shows the effect of an AFP surge in the patients ofthe
good/intermediate prognosis category: patients with a surge appear
to have an 8% worse treatment outcome than those whose markers
decline from day 1 onwards [HR 1.98 (surge/decline); CI
0.94-4.16; P = 0.07]. The fact that this P-value is only of border-
line significance should be related to the small number ofevents in
this subgroup.
Extent of AFP surge as a prognostic factor for time to
progression
Finally, thepotential effect ofthe percentage change in AFP values
(decline vs < 30% surge vs > 30% surge) on the time to progres-
sion was investigated both in a univariate and in a multivariate
model taking the IGCCCG classification into account (Figure 4).
The data suggest that the prognosis of the patients worsens
according to the extent of the surge, a larger percentage surge
being associated with a worse prognosis. The hazard ratio for the
extent of the surge was 1.68 (CI 1.24-2.29; P = 0.001) in the
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univariate analysis indicating a worsening of the prognosis by a
factor of 1.68 for patients with a < 30%7- surge compared with those
with a decline. or for those with a > 30% surge compared w-ith
those w-ith a smaller surgye (Figure 5). In the multivariate model
Awith the IGCCCG classification. the HR for the percentage change
in AFP w-as 1.67 (Cl 1.22-2.23: P = 0.001W. Even though these
analyses tend to confirm the prognostic value of a surge in AFP.
they should be regarded with caution because they are based on
ver- small numbers of events. particularly in the two groups of
patients with a surge.
DISCUSSION
For more than two decades it has been known that non-seminoma-
tous tumour cells may produce two glvcoproteins: alpha-feto-
protein which is produced by yolk sac elements and a-human
chorionic gonadotrophin w-hich is produced by trophoblastic
tumour cells. The concentration of these glvcoproteins in the
serum is concordant with the growth of the tumour. and the most
common pattern of marker response after the initiation of
chemotherapy is an exponential regression to normal levels.
However. durinn the initial weeks of treatment there may be a
transient increase of either one or both markers into the serum.
Possible explanations of this so-called marker surge phenomenon
have included the ongoing production of the glycoprotein by the
tumour cells. altered marker metabolism or excretion. and tumour
cell lysis with subsequent release of the glycoproteins into the
serum. The current notion assumes that a surge is related to tumour
cell lvsis. and that this may indicate a hiah sensitivity of the
tumourcells to the chemotherapy. However. after the initial reports
on the surge phenomenon (Vogelzang et al. 1982: Horwich and
Peckham. 1986). data have remained scarce and to date the prog-
nostic importance of marker surges is unclear.
Our present findings ofan adverse prognostic significance of an
AFP surge on progression discredits the assumption that marker
surges are associated with increased tumour cell lvsis. Because an
AFP surge clearly worsens the treatment outcome. the transient
increase in the serum. as yet followed by an exponential regres-
sion. must indicate the presence of tumour cells which are to a
lesser extent responsive to induction chemotherapy. The alterna-
tive explanation of ongoing proliferation of less sensitive tumour
cells does not provide a satisfying explanation either. It is not
likely that a fraction of tumour cells is able to increase marker
values to a sometimes greater than 300%7 rise within 1 week
merely by ongoing proliferation but. however. are killed for the
greater part by the same chemotherapy in the following weeks. as
evidenced by a subsequent exponential regression of marker
values. A possible explanation might be that a persistent fraction
of AFP-producing tumour cells responds to the chemotherapy by
shedding the glvcoprotein. but is not killed immediately by the
chemotherapy. Of note. in the past years we have observed several
patients. who appeared to do poorly. showing second and even
third AFP surgees in subsequent cycles of chemotherapy. Our orig-
inal interpretation was that these patients w-ho had largere tumour
burdens displayed protracted fractional cell kill. With the current
findinas at hand. AFP sheddingr by the partly chemoresistant
tumour cells may be a possible alternative. albeit speculative
explanation.
Althouah a similar trend of an adverse progrnostic significance
of an AFP surge was obsen-ed for the duration of survival. the
numbers of events were too low to reach statistical significance.
Hence. more data would be required to haxe enou-h statistical
power in that analysis.
WN'hether HCG surges ha-e a different biological nature is
unknown. Also. it cannot be excluded that w-e have missed HCG
surges occurring before day 8 that are already declining at the time
of our second measurement point. thereby confounding our
analxsis.
The implication of the finding of an AFP surge in terms of the
appropriateness of the actual chemotherapy beinc delivered to the
individual patient remains to be determined. BEP chemotherapy is
currently the standard regimen for all risk groups. and there is no
superior rerimen established. In addition. it is unknoU n whether
tumour cells giving rise to a surge are more effectively treated with
alternative treatment recimens. such as high-dose chemotherapy.
For these reasons. at the present time we do not recommend
sw-itchinc to alternative chemotherapy based upon the observation
of an AFP surge. outside the framework of a prospective clinical
studv addressing this issue. To date. the principal recommendation
is to rigorously keep to the standard BEP dose intensity. especially
in patients who have an indication to do less favourably by
showing an AFP surge.
We conclude that an AFP surge has an adverse prognostic
significance. that is independent of the pretreatment prognostic
characteristics. An AFP surre adds to the prognostic importance of
the current risk classification of the IGCCCG.
REFERENCES
Aass N. Klepp 0. Cavallin-Stahl E. Dahl 0. Wicklund H. Uinsgaard B. Baldetorp 1.
Ahlstrom S and Fossa SD 1991 Prognostic factors in unselected patients A ith
non-seminomatous metastatic testicular cancer- a multicenter experience.
J Clin Oncol 9: 818-826
Birch R. WAilliams S. Cone A. Einhorn L. Roark P. Turner S and Greco FA for the
Southeastern Cancer Study Group (1986) Prognostic factors for favourable
outcome in disseminated cerm cell tumours. J Clin Oncol. 4: 400-407
Bosl GJ. Geller Ni. Cirrincione C. Vogelzang NJ. Kenned! BJ. Whitmore A-F.
\ugrin D. Scher H. Nisselbaum J and Golbev RB (1983 M Multivariate anals sis
ofprognostic variables in patients w-ith metastatic testicular cancer. Cancer Res
43: 3403-3407
Cox DR (1972 Reeression models and life-tables. J R Statist Soc B34: 187-202
Cox DR and Snell EJ (I1989 .AnalYsis ofBinar- Data. 2nd edn. Chapman and Hall.
London
Droz JP. Kramar A. Ghosn MI. Piot G. Rev A. Theodore C. A-ibault P. Court BH.
Perrin JL. Travaeli JP. Bellet D. Caillaud JM. Pico JL and Ha\at MI 1988
Proanostic factors in ad anced non-seminomatous testicular cancer. Cancer62:
564-568
Hitchins R.N. New lands ES. Smith DB. Regent RHJ. Rustin GJS and BagshaAe KD
(1989 Long-term outcome in patients with germ cell tumours treated \kith
PONMB/ACE chemotherapy: comparison of commonly used classification
systems ofgood and poor prognosis. BrJ Cancer59: 236-242
Horbich A and Peckham N\U 1986 Transient tumour marker evaluation folloV inc
chemotherap! for germ cell tumors ofthe testis. Cancer Treat Rep 70:
1329-1331
tntemational Germ Cell Cancer Collaborati-e Group (1997(International Germ Cell
Consensus Classification: a prognostic factor-based staging s_vstem for
metastatic germ cell cancer. J Clin Oncol 15: 594-603
Kaplan EL and Meier P (1958 Non-parametric estimation from incomplete
obser ations. J.Am Stat .Assoc 53: 457-4881
Levi JA. Thoomson D. Sandeman T. Tattersall MI. Raghasen D. Byrne MI. Gill G.
Harvev \V Burns I and Sn\der R for the Australasian Germ Cell Trial Group
(1988 A prospecti e study of cisplatin-based combination chemotherap! in
advanced cerm cell malienanc\: role of maintenance and long-term follo\ -up.
J Clin Oncol 6: 1 154-1160
SMead G.M. Stenimne SP. Parkinson MC. Horsich A. Fossa SD. Wilkinson P.M. Ka\e
SB. Neswlands ES and Cook PA for the Medical Research Council Testicular
Working Parts 1992 The second medical research council study ofprognostic
factors in non-seminomatous cerm cell tumours. J Clin Oncol 10: 85-94
British Joumal of Cancer (1998) 78(10). 1350-1355 © Cancer Research Campaign 1998Aipha-fetoprotein surges in non-seminomatous testicular cancer 1355
Medical Research Counrcil Workine Partm on Testicular Tumours 19885 Prognostic
factors in advanced non-seminomatous germ-cell testicular tumours: results of
a multicentre studs. Lancet i: S- I1
Peckham NU. Horsich A. Easton DF and Hendn- F ( 1988) The mana2ement of
advanced testicular teratoma. BrJ Lrol 62: 63-68
Roth BJ. Greist A. Kubilis PS. Williams SD and Einhorn LH 1988 Cisplatin-based
combinationchefnotherapy for disseminated germ cell tumours: long-tern
follow--up. J Clin Oncol 6: 1239-1247
Stoter G and Sv vester R 1990) Prognostic factors in disseminated testicular cancer.
the EORTIC GU Group study results. J Cancer Res Clin Oncol. 116 suppl.):
950
Stoter G. Sylvester R. Sleijfer DT. Ten Bokkel Huinink A-W Kave SB. Jones WG.
Oosterorn Van AT. Vendrik CPJ. Spaander P and Pauw. De M 19871
Multivariate analhsis ofprognostic factors in patients with disseminated non-
seminomatous testicular cancer results from a European Organization for
Research on Treatment ofCancer multi-institutional phase mI study. Cancer
Res 47: 2714-2718
Stoter G. Koopman A. Vendrik CPJ. Struyvenberg A. Sleijfer DTH. W-illemse PHB.
Schraffordt Koops H. Oosterom Van AT. Bokkel Huininrk Ten WWU and Pinedo
HM1 1989 Ten- ear survi al and late sequelae in testicular cancer patients
treated w-ith cisplatin. vinblastine. and bleomrcin. J Clin Oncol 8: 1099-1104
Vogelzang NJ. Lange PH. Goldman A. Vessela RH. Fralev EE and Kennedy BJ (1982'
Acute changes ofaph-fetoprotein and human chorionic gonadoroin during
induction chemodthrapy ofgerm cell tumours. Cancer Res 42: 4855-4861
Wit De R. Stoter G. Sleijfer DTH. Kaye SB. Mulder De PHM. Bokkel Huinink Ten
WW. Spaander P. Pauw De M and SNIvester R 1995) Four cvcles of BEP
versus an alternatingy regime ofPVB and BEP in patients A-ith poor-prnosis
metastatic testicular non-semirnoma: a randomi'sed studv ofthe EORTC
Genitourinar- Tract Cancer Cooperative Group. BrJ Cancer 71: 1311-1314
Wit De R. Stoter G. Kave SB. Sleijfer DT. Jones WG. Bokkel Huinink Ten WV:
Rea LA. Collette L and Sylester R (1997 The importance ofbleom cin in
combination chemotherapy for good prognosis testicular non-seminoma: a
randomized studv ofthe EORTC Genitourinary Tract Cancer Cooperative
Group. J Clin Oncol 15: 1837-1843
0 Cancer Research Campaign 1998 British Joural of Cancer (1998) 78(10), 1350-1355